Omeros (NASDAQ:OMER) Stock Price Down 3.1% - Time to Sell?

Omeros Co. (NASDAQ:OMER - Get Free Report)'s share price fell 3.1% on Monday . The company traded as low as $10.61 and last traded at $10.86. 44,701 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 459,604 shares. The stock had previously closed at $11.21.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on OMER shares. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a report on Thursday, December 19th. D. Boral Capital began coverage on shares of Omeros in a report on Monday, December 23rd. They set a "buy" rating and a $36.00 target price for the company. Rodman & Renshaw assumed coverage on Omeros in a research note on Thursday, November 14th. They issued a "buy" rating and a $9.00 target price for the company. RODMAN&RENSHAW raised shares of Omeros to a "strong-buy" rating in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Omeros in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Stock Down 3.3 %

The stock has a fifty day moving average of $8.32 and a two-hundred day moving average of $5.64. The stock has a market cap of $628.18 million, a price-to-earnings ratio of -4.69 and a beta of 2.01.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP acquired a new position in Omeros during the third quarter worth $305,000. Barclays PLC raised its stake in shares of Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company's stock worth $376,000 after buying an additional 51,873 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company's stock worth $887,000 after buying an additional 31,081 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Omeros in the 2nd quarter valued at about $105,000. Finally, SG Americas Securities LLC purchased a new position in Omeros during the 3rd quarter valued at about $80,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.